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We have used a murine proximal tubule cell line (MCT cells) to determine the presence and binding characteristics 
of insulin a~d IGFI receptors and to correlate these parameters with the cnncentration-response relationships for 
ligand-indueed cellular proliferation. Separate insulin and IGFI receptors were identified by equilibrium binding 
assays. Half-maximal displacement of either peptide e-curred at 3-10 nM; crossov~ binding te the alternate 
receptor occurred with a I0- to 100-fold lower affinity. Peptide effects on cellular proliferation were determined by 
measuring [3H]thymidine incorporation. Both insulin and IGFI stimulate thymidine incorporation in a dose-de- 
pendent manner with similar increases above the basal level. The estimated half-maximal stimulation (EC~) 
occurred at 4 nM for !GFI and g nM for insulin. A comparison of the receptor binding affinities with the 
dose-response r lationships for [~H]thymidine incorporation reveals that each growth factor appears to be exerting 
its effect via binding to its own receptor. Therefore, in this cell line, physiologic oncentrations of either insulin or 
IGFI can modulate cellular growth. To our knowledge this is the first demonstration ofa mitegenie ffect whiel~ may 
be modulated by ligand binding to the insulin receptor in proximal tubule epithelia. 
Introduction 
Insulin and insulin-like growth factor 1 ( IGFI)  are 
structural!y related peptide~ whose functions are 
thought o have diverged uring evolution. In general, 
insulin functions as an endocrine hormone which is 
critical in the control cf eai'bohydrate, protein and lipid 
homeostasis. In contrast, IGFI is classically considered 
a regulator of cellular growth and differentiation. In- 
terestingly, however, in certain tissues the two peptides 
can also mediate similar cellular effects such as the 
stimulation of substrate and ion transport [1-3] and 
cellular proliferation [4-8]. 
Each peptide binds with high affinity to distinct 
receptors and it is this specific ligand-receptor interac- 
tion which initiates the physiological effects of the 
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peptide. Overall the: insulin and tUFt receptors hare 
remarkable homology both in primary structure and in 
organization. Not surprisingly, therefore, insulin and 
IGFl exhibit crossover binding to the heterologous 
receptor, however, crossover binding occurs with a 
significant (10-100-fold) decrease in affini~ [3,9-11]. 
The crossover binding phenomenon is often evoked to 
explain an apparent crossover in physiological effect. 
For example, insulin is a required component for 
growth of mammalian cells which are maintained in 
tissue culture using serum-free, defined media. Typi- 
cally the growth-stimulatory effects of insulin are 
achieved at pharmacologic concentrations (1 ~g/ml  or 
greater) [12-18]. In contra~t, the effecls of IGFI on 
cellular proliferation are often manifested at much 
lower ti.e., physiological) concentrations [2,9,11 ]. These 
findings suggest hat the growth stimulatory effects of 
both insulin an/  IGFI are manifested via binding to 
the IGFI receptor. In contrast, several recent studies 
have suggested that in certain fibroblastic ell types 
both insulin and IGFI can modulate cell growth via 
binding to their homologous receptors [5]. 
lnsutin and ~3F! receptors co-exi,,t on the same 
cells in many tissues. In the maa~m:~lian kidney, both 
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receptors have been demonstrated on glomerular 
mesangial cells [2] and proximal tubular epithelial cells 
[19,20]. In addition, in renal tissue, both insulin and 
IGF1 have been demonstrated to stimulate solute and 
fluid reabsorption [3,21-23] as well as promote growth 
in cell culture [24,25]. The co-existence of two recep- 
tors, each capable of binding either ligand, necessitates 
a careful correlation of binding affinities with physio- 
logical effect before a functional response can be as- 
cribed to activation of either receptor. 
In this study we used a proximal tubule cell line to 
test whether cellular proliferation is modulated by lig- 
and binding to insulin and/or IGFI receptors. The 
mouse cortical tubule (MCT) line was originally de- 
rived from microdissected proximal tubule segments 
from normal mice, immunoselected into a homoge- 
neous cell populat,.'or, and stabilized in long-term cul- 
ture by SV40 transformat],_,n [26]. This is a well charac- 
terized cell line which has proveu to be a good model 
in which to investigate growth of proximal tubule cells 
under a variety of metabolic [27,28] and hormonal 
conditions [29]. Portions of this work have been pre- 
sented in abstract form: Blazer-Yost, B.L., Watanabe, 
M., Haverty, T. and Ziyadeh, F.N. 11990) J. Am Soc. 
Nephrol. 1,453A. 
Materials and Methods 
Media for cell culture were obtained from Gib,.-o 
(G~aud island, NY). Recombinant human IGF1 (THR- 
59) was purchased fr._,,n.. AMGer.. Biologicais (Thou- 
sand Oaks, CA). IGFI stock solutions (#M) were 
prepared in 0.01 M HCI and stored at 5°C. IGFI was 
iodinated to a specific activity of 1600-2300 Ci/mmol 
using a modified chloramine-T procedure [30]. Porcine 
insulin was kindly provided by Lilly Research (Eli Lilly, 
Indianapolis, IN). Insulin stock soiutions (raM) were 
prepared in 0.0{)5 M HCI and stored at 5°C. ~251-1abeled 
porcine inst, lin, 2200 Ci/mmol, was purchased from 
New England Nuclear (Boston, MA). [3H]Thymidine, 5
Ci/mmol, was obtained from Amersham (Arlington 
Heights, IL). Disuccinimidyl suberate was obtained 
from Pierce Chemical (Rockford, IL). Disuccinimidyl 
suberate stock (5.10 -3 M) was prepared in DMSO 
immediately before use. Electrophoresis grade reagents 
for polyacrylamidc gel electrophoresis (PAGE) were 
purchased from Bio-Rad (Richmond CA). All other 
reagents were highest quality available and were ob- 
tained from commercial sources. 
Cell Cultltre. The isolation and characterization of 
the MCT cell line were provided previously [26]. Multi- 
ple morphological nd functional properties of this cell 
line are consistent with those of differentiated proxi- 
mal tubule epithelial cells [26-28]. Briefly, the ceils 
stain positive for cytokeratin and alkaline phosphatase 
and demonstrate apical microvilli and lateral tight 
junctions by electron microscopy. The cells respond to 
treatment with parathyroid hormone by an increase in 
cyclic AMP content [29]. In the studies described here, 
the culture medium was a 1 : 1 mixture of Dulbecco's 
modified Eagle's medium (DMEM) and Ham's-Fl2 
(HFI2), supplemented with 100 /zg/ml streptomycin, 
100 U/ml penicillin, 2 mM glutamine and 5 #.g/ml 
human transferrin. The cells were passaged every 48-72 
h and were carried in culture medium supp!emented 
with 10% inactivated fetal calf serum. Cultures were 
maintained in a humidified atmosphere of 5% CO 2 at 
37°C. 
Competitire binding studies. In .:hose experiments 
where competitive binding of insulin and 1GF1 to MCT 
cells was determined, the cells were seeded onto 24 
well tissue culture plz~tes (density= 10 "~ cells/well). 
The cells were maintained in normal media for 24 h, 
then placed in serum-free media for 24-48 h prior to 
assay. Confluent cellular monolayers were washed and 
incubated at room temperature for 90 rain in bindi,ig 
buflX:r (serum-free medium, 0.2% BSA, 25 mM Hepes, 
pH 7.4) containing (3-4)-10 -"~ M [~2Sl]insulin or 
[I~Sl]IGFI and unlabeled competing peptides as indi- 
cated. At the end of the incubation period, the cells 
were washed three times with ice-cold phosphate- 
buffered saline and solubilized in 1 M NaOH, 0.1% 
Triton X-100. Aliquots of the solubilized cellular mate- 
rial were counted in a gamma scintillation cout:ter. 
Nonspecific binding was defined as the number of 
counts bound in the presence of 10 -7 M unlabeled 
peptide and this value was subtracted from all samples. 
In every experiment duplicate or triplicate assay wells 
were performed for each concentration. Nonspecific 
binding was less than 20% of total binding. 
To further define the binding specificities of the 
receptor subunits, cells were incubated in binding 
buffer with (3-4). I0 -I° M [t251]IGF1 in the presence 
or absence of unlabeled competing peptides. After a 90 
min incubation period at room temperature, the cells 
were washed twice with cross-linking buffer (0.1 M 
Hepes, 0.12 M NaCI, 5 mM KCI, 1.2 mM MgSO 4, 8 
mM glucose and 10 mg/ml BSA, pH 8.0). The bound 
peptide was covalently cross-linked to the receptor by a 
15 rain incubation with 0.1 mM freshly prepared isuc- 
cinimidyl suberate in crosslinking buffer, The reaction 
was terminated by the addition of 0.1 M Tris (pH 8.8). 
The cells were washed and solubilized in SDS-PAGE 
buffer (3% SDS, 10% glycerol, 1% j0-mereaptoethanol, 
0.05 M Tris, pH 6.8). The solubilized samples were 
stored at - 20°C. 
PAGE. SDS-PAGE was performed on 15 × 13 cm 
slab gels with a linear 5-15% acrylamide gradient and 
a 4% stacking el. The aliquots applied to the gel were 
matched for cell num0er. The preparations were sub- 
jected to eleetrophoresis under constant current condi- 
tions (30 mA/gel for 20 min followed by 25 mA/gel 
for 4 h). The gels were then fixed, dried and exposed to 
Kodak XAR-5 film in cas:mttes containing X-Omatic 
fine intensifying screens (Eastman Kodak, Rochester, 
NY). 
[';H]Thymidine incorporation studies. Cells in culture 
were released by t~psin-EDTA, washed twice in 
serum-free medium and adjusted to a final concentra- 
tion of 1 • 10 ~' celis/ml. 10000 cells were subcultured in
fiat-bottom 96-microtiter wells, each containing 200 ~1 
serum-free medium. After 48-72 h of quiescence the 
media were removed and replaced with fresh serum- 
free medium without or with the addition of various 
concentrations of insulin or IGFI  as noted in the text. 
All growth studies were performed on rested cells at 
approx. 70% subconfluence. Cells were allowed to grow 
for an additional 24 h. During the last 6 h of culture, 
the cells were pulsed with ["q]thymidinc (1 p.Ci/well). 
The media were removed amt the cells were released 
with trypsin-EDTA for subsequent lysis and collection 
with a cell harvester (13randel, Gaithersburg, MD) onto 
glass-microfiber filter paper (934-AH, Whatman, U.K.). 
The incorporated radioactivity in cellular nuclei was 
as,~ayed by counting filters in scintillation cocktail. 
[3H]Thymidine incorporation i to cell DNA was take~ 
as an index of cell proliferation and was expressed in 
counts per mix per well. Each experimental condition 
was tested in four to six replicate wells and the mean 
was taken to represent an individual experiment. In 
parallel experiments, measurements of cell number 
were performed in order to verify that the observed 
increase in thymidine incorporation was associated ~ith 
an increase in cell number. 
Statistics. The data are presented as means + S.E. 
with n indicating the number of different experiments. 
Comparisons were performed using Student's t-test for 
paired or unpaired values as appropriate; values of 
P < 0.05 were considered sil~nificant. Binding studies 
were analyzed graphically. 
Results 
Competitive binding studies 
Equilibrium binding assays were performed to de- 
termine the presence and specificity of insulin and 
IGF1 receptors on MCT cells. Fig. 1 illustrates the 
specificity of human recombinant IGF1 binding: half 
maximal displacement of [t251]lGF1 oc,:urs at an unla- 
beled IGF1 concentration between 3 and 10 nM. In- 
sulin was an effective competitive ligand only at ap- 
prox. 100-fold greater concentrations. Fig. 2 illustrates 
the specificity of binding of porcine insulin: half maxi- 
mal displacement of [~251]insulin occurs at an unla- 
beled insulin concentration between 3 and 10 nM. 
IGF1 also displaced insulin but only at approx. 10-30- 
fold greater concentrations. Thus, the affinity of insulin 
for the insulin receptor is very similar to that of IGFI  
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Fig. 1. Competitive binding curve for [Iz~I]IGFI in the m{:z:se proxi- 
mal tub~fle cell line. Maximal binding is defined as the amount of 
12Sl]IGFI specifica yb{ und by intact cells in the absence ~t" unla- 
b:~led peptide. [125111GFI bound in the presence ofvarious c{mcen- 
trations of unhlbelcd competing li ands i expressed asa percentage 
of the maximal level (q- max). Non~pecific binding is defined as the 
number of counts bound in the presence of 1OO nM IGFI and is 
subtracted from all values. Points shown at each com, entvafion 
represent the mean of lhree separate xperiments. The standard 
error of the mean is indicated by vertical bars. When ne bar~ appear, 
the stv_ndard error is less than the symbol used to designate he mean 
value, o - -o .  IGFh o - -Q .  insulin. 
for the IGFI receptor; crossover binding to each recep- 
tor does occur but only with a 10- to 100-fold lower 
affinity. 
The relative number of insulin and IGFI receptors 
appears to differ in MCT cells. Using our standard 
incubation conditions with approximately equal con- 
centrations of peptides which had been iodinated to a 
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Fig. 2. Competifive binding curve for [l~l.jinsu|in in the mouse 
proximal tubule cell line. Maximal binding is defined as the amount 
of [:'-~l]insulin specifically bound by intact cells in the absence of 
unlabeled peptide. [lZ~l]lnsulin bound in the presence of various 
concentrations of unlabeled competing ligands is expressed as a 
percentage of the maximal level (% max). Nons~cific binding is 
defined as the number of counts bound in the presence of 100 nM 
insulin and is subtracted from all values. Points shown at each 
concentration represent the mean of three separate xperiments. 
The standard error of the mean is indicated by vertical bars. When 
no bars appear, the standard error is less than the symbol used to 
designate he mean value, o - -o .  IGFh o - -o .  insulin. 
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Fig. 3. [U~lJlOFI binding to mouse proximal tubule cell receptor 
subunils in the presence of various concentric:ions of unlabeled IGFI 
and insulin. To show that receptor specificity was manifested at the 
level of the a subunit of the IGFI receptor, selected samples from 
the competitive binding curves were treated with the crosslinking 
reagent disuccinimidyl suberate to eovalently couple bound ligand to 
the receptor. The crosslinked samples were solubilized in a reducing 
buffer, separated by one-dimensional PAGE and visualized by ~,.~fto- 
radiography. Unlabeled competing ligands (final concentrations i di- 
cated) were present in the incubation buffer hclore crosslinking, The 
arrow indicates tile posilion of tile a subunit o[ the leCea!ol. 
Positions of the molecular mass markers (in kDa) are indicate. 
kDa) h:md ;:, these studies likely results from the 
crosslinkin8 ol a/fl and/or  a/a receptor subunits by 
the divalent crosslinking reagent, disuceinimidyl sub.r -  
ate [2]. Due to the extremely low number of insulin 
receptors, we were unable to incorporate sufficient 
[JzsI]insulin to analyze the [I251]insulin binding curves 
by PAGE. 
[~H]Thymidine incorporation studies 
Peptide effects on cellular proliferation were deter- 
mined by measuring [3H]thymidine incorporation in 
the presence of various concentrations of ~nsulin and 
IGF1 (Fig. 4). Both insulin and IGFI stimulated th,:mi- 
dine incorporation in a dose-dependent manncr  with 
similar maximal increases above the basal level. The 
estimated half-maximal stimulation (ECsa) is 4 nM for 
IGFI and 8 nM for insulin; these concentrations fz:l 
within the physiologic range of either peptide. 
A maximal effect of IGF1 on cellular p:oliferation 
appears to be manifested within a narrow concentra- 
tion range. Maximal [3H]thymidine incorporation was 
achieved at l0 nM and further increases in peptide 
concentration result in a submaximal proliferative re- 
sponse (Fig. 4} 
To confirm the ability of insulin to stimulate cell 
proliferation, pa la l ld  ~ubconfluent cultures in 12-well 
plastic plates were incubated in the presence and ab- 
sence of 32 nM insulin. At the end of the 48 h 
incubation period the control cultures contained 6.75 
+0.36 .105  cells/well  while the insulin treated cul- 
tures contained 8.95 + 0.61 • 105 cells/well (n = 5, P < 
0.05). 
similar specific activity, 3 -6% of the ['251]IGF1 was 
specifically bound by the MCT cells; in contrast, only 
0.1-0.4% of the [USl]insulin was specifically bound in 
this cell line. 2.5 T 
To show that the binding specificity was manifested ~ 
at the level of the a-subunits of the MCT receptors, in | 
some competitive binding experiments he bound IGFI  "~ .1. 2.0-- 
was crossliuked to the receptor with disuccinimidyl o 
1 suberate. Fig. 3 illustrates [JzsI]IGFI binding to MCT cells in the presence of various concentrations of unla- ~, beled IGF1 or insulin. Maximal '2"Sl incorporation into :_ ~.5 
proteins having an apparent molecular mass of 130 
kDa is observed in samples incubated with no compet- g ~.0 
ing ligand or with 1 nM unlabeled IGFI .  As antici- 
pated from the competitive binding curves, 100 nM ~ 0 
unlabeled IGFI completely inhibited the binding of 
[I"51]IGFI, whereas 10 nM IGFI partially inhibited 
binding. 100 nM unlabeled insulin only slightly inhib- 
ited the binding of ['251]IGFI. The presence of low 
concentrations of insulin (1 aud 10 nM) did not inhibit 
and m.w stimulate [1251]lGF1 incorporation. The basis 
for this apparent increase in IGFI binding in the 
presence of physiological concentrations of insulin is 
unknown. The diffuse high molecular mass (> 200 
. n=7 
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Hormone oncenlrotlon (riM) 
Fig. 4. Comparison of tritiated thymidine incorporation i response 
to insulin and IGFI in proximal tubule cells. [3H]Thymidine incorpo- 
ration in respogse to various concentrations of insulin and IGFI is 
expressed relative to control culture~ which were mcubated in 
serum-free media during Ihe experimental perlon "/'h,.' data shown 
represent seven separate xperiments. The standard errors of the 
mean are indicated by vertical bars. * indicates concentrations where 
the responsc:~ to insulin and IGFI are statistically different (P  < 0.02). 
O-- -O .  insulin; e - -e ,  IGFI. 
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Fig. 5. Response of tritiated thymidine incorporation i  proximal 
tubule cells to the combined treatme,lt with IGFI. insulin and EGF. 
The bars illustrate the counts of [3H]thymidine incorporated by the 
cultured cells in response to submaximal concentrations of insulin 
and IGFI (At, maximal concentrations of insulin and IGFI (B) lind a 
maximal concentration of EGF (lO ng/ml) i,1 ct~mbination with 
maximal concentrations of insulin and IGFI (C). The vertical lines 
represent s andard errors of the mean. The combined treatment with 
submaximal doses ,.)f IGFI and insulin elicits an additive ffect 'm 
thymidine incorporation which is significant!y (P < 0.05) higher th~:n 
that exhibited by either hormone alone (*). When maximal doses (;f 
either IGFI or insulin are combined with epidermal growth factor 
(EGF, lit ng/ml), the stimulation in thymidine incorporation is
significantly ~P < 0.(15) higher than that exhibited by treatment with 
EGF alone (+ ). 
We have also cxan|ined the proliferative response to 
incubation with combinations of insulin, 1GFI and 
epidermal growth factor (EGF) (Fig. 5). Incubation 
with submaximal doses of IGFI and insulin (3.2 nM) 
resulted in a significantly higher stimulation of th~,mi- 
dine incorporation compared zo that elicited by either 
hormone alone. In contrast, the combined treatment 
with maximal doses of IGF1 and insulin (32 nM) pro- 
duced a proliferative stimulation that was not different 
from the response to either hormone alone. When 
maximal doses of either IGFI  or insulin (32 nM) are 
combined with epidermal growth factor (10 ng/ml) ,  
the stimulation in thymidine incorporation was signifi- 
cantly higher than that exhibited by treatment with 
EGF  alone. A combination of maximal doses of EGF 
and IGFI (or insulin) also stimulates thymidine incor- 
poration to a significantly higher (P  < 0.05) level than 
either IGFI  or insulin alone (data not shown). 
Discuss ion  
In the kidney insulin is thought to modulate 
metabolic and transport functions while IGFI is con- 
sidered to be a regulator of growth and differentiation 
[21,31,34]. Many of the studies which have given rise to 
this general concept have used intact organs or mem- 
branes isolated from specific areas of the kidney. While 
such studies have been extremely valuable in establish- 
ing the functions of various nephron segments, it is 
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difficult to precisely determine the role of growth fac- 
tors and metabolic modulators in these experimental 
systems. A comindous cell line derived from a defined 
area of the kidney tubule provides the cellular homo- 
geneity and st~tbi!i,~y necessary to assess the contribu- 
tion of various fact,~rs to the growth of a specific cell 
type. In this study we used the MCT cell line as a 
model For proximal tubule ceil growth. Previous investi- 
gations have demonstrated that this cell line retains the 
characteristics of differentiated proximal tubule ceils 
and provides a suitable model to investigate prolifera- 
tion of renal epithelia [26-29]. 
While the physiological role of insulin in renal 
glowth remains unclear, it is known that kidney cells in 
culture require insulin in the supporting medium. Hor- 
mone-supplemented, serum-free medium has been de- 
scribed for maintenance of the Madin-Darby canine 
kidney (MDCK) cell line [12], the LLC-PKI epithelial 
cell line from pig kidney [15], and for primary cultures 
of canine renal epithelia [13], baby mouse kidney cells 
[14] and rabbit kidney epithelial cells [16,17]. IGFI was 
not a component of the hormone supplements but 
insulin was present in micromolar concentrations, l'he 
assumption, explicit or implicit, is that -".t these supra- 
physiological concentrations insulin modulates growth 
and differentiat;on via crossover binding to IGFI re- 
ceptors. However, this assumption may not be valid for 
all cell types. 
Physiological concentrations of either insulin or 
IGFI promote cell growth and proliferation via bindin': 
to their homologous receptors in a rat osteosarcoma 
cell line, UMR-106-01 [8] and in Swiss 3T3 fibroblasts 
[6] as well as in normal skin fibroblasts i~ primary [4] 
and continuous [7] culture. In a careful stlidy, Furlan- 
ctt6 ct ai. [5i used specific anti-receptor ant!bodies to 
show that insulin, working via an insulin receptor, was 
not mitogenie in two lines ef  human embryonic lung 
fibroblasts but, under identical conditions, was milo- 
genic in a human dermal fibrobiast cell line, a human 
embryonic skin fibroblast line and an osteogenic sar- 
coma cell 1inc. Thus, it appears that, altlaough activa- 
tion of IGFI receptors is uniformly capable of mediat- 
ing a mitogenic response, the ability of activated in- 
sulin receptors to stimulate proliferation is cell-specific. 
Both insulin and IGFI receptors have previously 
been demonstrated on proximal tubular epithelia 
[19,20,32]. In agreement with these studies, we have 
found that mouse proximal tubule cells in culture also 
contain two separate receptors, each with similar dis- 
placement curves (Figs. 1 and 2). The affinity of insulin 
for the insulin receptor is very similar to that of IGFI 
for the IGFI receptor; crossover binding does occur 
but only with 10-100-fold lower affinity. The displace- 
ment curves for insulin and IGFI binding to their 
specific receptors are very similar to those reported in 
other tissues and cell lines [2,3,11,33]. Insu l in / IGF l  
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hybrid receptors have been assembled in vitro [35] and 
!lave been identified ~n NIH3T3 and HepG2 cells [36] 
and in transt'ec'~ed ro ent cells which overe;~press hu- 
man insulin and IGFI receptors [37]. Our binding 
curves are consistent with the exist~tnce of separate 
insulin and IGFI receptor populations, howcver, we 
cannot rule out the existence of a small number of 
insulin/IGF receptor hybrids. The molecular weight of 
the a subunit of MCT cell IGFI receptor is comparable 
to other IGFI receptors [38] and the ligand binding 
specificity is manifested at the level of the. ot subunit 
(Fig. 3). 
In our studies the amount of IGFI specifically bound 
by the proximal tubule cells was at least an order of 
magnitude greater than that of insulin indicating a 
relatively higher number of IGFI receptors. This is 
similar to isolated rat renal tubules [33] and cultured 
rat renal mesangial cells where specific binding of 
[1251]IGFI was > 200-fold higher than insulin binding 
[2]. in contrast, the specific binding of insulin was 
approx. 4-fold higher than that of IGFI in proximal 
tubular basolateral membranes prepared from canine 
kidneys [32]. It is unknown whether the differences in 
magnitude of receptor expression in the proximal 
tubule represents natural differences in species, het- 
erogeneity in cell type found in intact kidney or changes 
in receptor expression during the process of cellular 
immortalization. 
Both insulin and IGFI stimulate [3H]thymidine in- 
corporation iv proximal tubule cells with an ECs, be- 
tween 3 and 10 nM; a maximal dose of IGFI stimu- 
lated thymidine incorporation 2.2-fold, while a maxi- 
mal concentration of insulin eliciled a 2-told stimula- 
tion. A comparison of the receptor-ligand binding 
affinities (Figs. 1 and 2) with the dose-response r la- 
tionships for [3H]thymidine incorporation (Fig. 4) re- 
veais that each growth factor appears to stimulate 
growth via binding to its own reeeptt~r. Therefore, in 
this proximal tubule cell line, physiologic oncentra- 
tions of either insulin or IGFI can modulate <ellular 
growth. It is possible that the slightly higher pntency 
and magnitude of stimulation by !GFI is due to the 
higher density of the IGFI receptor compared with 
that of the insulin receptor. 
To our knowledge this is the first demonstration f a 
mitogenic effect which may be modulated by ligand 
binding to the insulin receptor in proximal tubule ep- 
ithelia. Very little, in general, is known regarding 
growth effects of insulin on epithelial cells. In contrast, 
IGFl has been implicated as a major growth factor in 
re~al tissue. Renal hypertrophy is a manifestation of 
acromegaly [39] which is characterized by an increase 
in circulating IGFI levels, in addition, in response to 
certain stimuli, such as the loss of renal mass, the 
cortical attd medullary collecting duct cells of the mam- 
malian kidney are known to synthesize IGFI [34,40-42]. 
The demonstration f specitic receptors fnr IGFI in 
the proximal tubule support the concept of a paracrlne 
'loop' for IGFI [34]. 
Interestingly. maximal sthnulation of [3H]thymidine 
incorporation occurs at all insnlin concentrations mea- 
sured at and above 32 riM, whereas IGFI is only 
maximally effective over a very narrow concentration 
range. A similar sharp decrease in the magnitude of 
1GFI stimulation of [3H]thymidine incorporation at 
peptide levels above 10 nM has been demonstrated in 
cultured rat renal mesangial cel!s [2]. This relatively 
narrow effective concc~,tration range may be physio- 
logically relevant. However, a complete understanding 
of this phenomenon is limited by imprecise measure- 
ments of effective in vivo concentrations of IGFI. 
In vivo, insulin levels in the circulation vary widely 
and rapidly according to the metabolic requirements of 
the organism. Despite this fluctuation, the effective 
circulating concentration o! insulin is known to be 
much lower ~han the total concentration of IGFI. 
IGFI, unlike insulin, is bound by several high affinity, 
soluble binding proteins which may modulate 
pcptide-receptor interactions and, therefore, the ef- 
,¢eetive circulating concentration is difficult to ascertain 
[11,31]. Also, in contrast to insulin, IGFI is a paraetine 
or autoerine factor in the kidney [34]. 
Although the growth stimulator,/responses to both 
in~,i:,i and IGFI appear to be initiated by ligand 
binding to distinct receptors, the cascade of events that 
culminate in cell proliferation may overlap at a point 
subsequent to ligand-reeeptor binding. The stimulatory 
response to a combination of maximal concentrations 
of both insulin and IGFI is not statistically greater 
than the response to a maximal stimulation of either 
peptide alone (Fig. 5). This was not due to the inability 
of the epithelium to show a further increase in thymi- 
dine incorporation: a maximal concentration f EGF in 
combination with a maximal concentration of insulin 
stimulates MCT cells to a greater degi-ee than either 
peptide alone. 
A similar overlap in the intracellular pathways stim- 
ulated by insulin and IGFI has been observed in the 
toad urinary bladder, a model of the mammalian distal 
nephron [3]. In this high resistance pithelium insulin 
or IGFI binding to distinct receptors timulates .~ran- 
scellular Na + flux. The natriferic pathways activated by 
insulin and IGFI appear to converge subsequent to 
ligand-receptor binding but prior to the final transport 
stepts). The ~enerality of this post-receptor conver- 
gence in intraeellular pathways remains to be tested. 
The role of IGFI as a renal growth factor has been 
delineated by various studies; the role of insulin in 
renal growth remains more elusive. The current data 
suggest that insulin may be an important factor in renal 
cell proliferation. This peptide may play a role in 
repair and recovery after insult or may be important as 
a maintenance  fa~.tor dur ing  normal  epithcl iz '{ tu rnover  
and  regenerat ion ;  however ,  the  exact  funct i ( ,a  o~. in- 
su l in -s t imu la ted  pro l i fe ra t ion  remains  to be  :tt: , ted. 
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